Sarepta Therapeutics to Request Expansion of Elevidys to All Age Groups Following Study Results
By Denny Jacob
Sarepta Therapeutics said it will request expanding its Duchenne muscular dystrophy treatment to patients in all age groups following results of a study.
The commercial-stage biopharmaceutical company said study participants treated with Elevidys showed an increase on the North Star Ambulatory Assessment, a measure of motor function, compared to placebo-treated patients at 52 weeks, although the primary endpoint wasn't met.
Sarepta said the study of Elevidys supports the conclusion that the treatment modifies the trajectory of people dealing with Duchenne. The Phase 3 clinical study of Elevidys evaluated the treatment in patients with Duchenne between the ages of four and seven.
Elevidys received accelerated FDA approval for patients ages four through five in June.
Based on the results of the study, "we intend to move swiftly to request an update to expand the labeled indication to treat all patients," said Chief Executive Doug Ingram. He added that the leadership at the Food and Drug Administration confirmed that, based on the evidence so far, they are open to such an expansion if supported by a review of the data.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
October 30, 2023 17:02 ET (21:02 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?